Hepcludex (Bulevirtide)

Hepcludex is a prescription antiviral medication that contains the active ingredient bulevirtide at a strength of 5 mg per vial, supplied as a sterile injection solution for subcutaneous administration. It belongs to the viral entry inhibitor class and is approved in the European Union for the treatment of chronic hepatitis D infection in adults with compensated liver disease. The product is marketed under the brand name Hepcludex.

Hepcludex is indicated for specific clinical situations related to hepatitis D virus infection.

- Chronic hepatitis D infection in adults with compensated liver disease. - Patients who have documented HBV co‑infection, as hepatitis D requires hepatitis B surface antigen for replication. - Cases where antiviral therapy is needed to prevent progression to cirrhosis. - Use as part of a comprehensive management plan that includes monitoring of liver function. - May be considered when other hepatitis D therapies are unavailable or contraindicated.

The safety profile of Hepcludex includes several reported adverse events, which are categorized by frequency and severity.

Common: - Injection site pain or erythema. - Mild fatigue. - Transient headache. - Elevated liver enzymes (ALT/AST) that are usually reversible.

Serious: - Severe hypersensitivity reactions, including rash or anaphylaxis. - Significant hepatic decompensation or worsening liver function.

Before initiating Hepcludex, clinicians should evaluate several precautionary factors to ensure safe use.

- Confirm compensated liver disease status; decompensated cirrhosis requires careful assessment. - Assess for active HBV infection and ensure appropriate HBV management. - Monitor liver function tests regularly during therapy. - Use with caution in pregnant or breastfeeding women, as safety data are limited. - Evaluate renal function, although no specific contraindication is known. - Review patient’s allergy history, especially to injectable products. - Consider potential immunosuppression that could affect infection risk.

Hepcludex may interact with other medicines, and the nature of the interaction guides clinical decisions.

Avoid: - Concomitant use of potent NTCP inhibitors that could alter bulevirtide pharmacodynamics (experimental agents). - Live vaccines administered during treatment, due to possible reduced immune response.

Use with caution: - Other antiviral agents targeting hepatitis B (e.g., tenofovir, entecavir) as combined effects on viral replication are not fully characterized. - Immunosuppressive drugs, which may affect infection control. - Medications that significantly affect liver enzymes, potentially altering bulevirtide metabolism.